.Attribute Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ innovative breast cancer cells and also active or stable brain metastases revealed constant intracranial task and wide spread efficiency of T-DXd.